Biote Corp. (BTMD)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$1.550.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · BTMD
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Advance strategic initiatives to drive sustainable procedure revenue growth and improve financial performance in second half of 2026.
Stated as a priority in 3 of last 3 quarters. Procedure revenue declined year-over-year by 13.2% in 2026-Q1 to $31.3M and by 13.9% in 2026-Q2 to $30.3M, reflecting impacts from a voluntary product recall. Management expects sequential improvement in procedure revenue in Q3 and Q4 2026 but year-over-year growth remains negative in the near term. The trajectory shows ongoing recovery efforts with limited progress so far.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Interim CEO: 'We believe foundational improvements position the Company to achieve sustainable procedure revenue growth.'”
“CEO: 'Focused on restoring sustainable procedure revenue growth; expect return to growth in second half of 2026.'”
“Management: 'Return to procedure revenue growth in second half of 2026, consistent with guidance.'”
Maintain disciplined execution to achieve Adjusted EBITDA above $25 million for full year 2026 despite first half challenges.
Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA declined from $8.7M in 2026-Q1 to $5.6M in 2026-Q2, reflecting lower revenue and higher expenses. Management revised full-year 2026 guidance to Adjusted EBITDA above $25M, down from prior $38M guidance, reflecting first half performance. The trajectory shows limited progress with downward revision.
“Management: '2026 guidance Adjusted EBITDA above $25 million, revising outlook to reflect first half performance.'”
“Management: '2026 guidance Adjusted EBITDA above $38 million, reaffirmed earlier in the year.'”
“Management: '2026 guidance Adjusted EBITDA above $38 million, reaffirmed in prior disclosures.'”
Manage leadership transition with appointment of interim CEO and maintain operational discipline and strategic progress.
Stated as a priority in 2 of last 3 quarters. Leadership transition occurred in mid-2026 with Bob Peterson named Interim CEO. Management emphasizes continuity and operational discipline during transition. No direct financial impact cited but leadership stability is highlighted as critical to executing strategy.
“Interim CEO Peterson: 'Honored to lead as we pursue growth and operational scaling.'”
“CEO Christensen: 'Leading the company through strategic priorities and growth.'”
Continue to grow dietary supplements revenue at mid to high single digit rate from 2025 levels.
Stated as a priority in 2 of last 3 quarters. Dietary supplements revenue grew 19.1% in 2026-Q1 to $11.0M and 5.7% in 2026-Q2 to $11.4M year-over-year. Management expects mid to high single digit growth for full year 2026, consistent with prior guidance. The trajectory shows delivering growth in this segment.
“Dietary supplements revenue grew 5.7% to $11.4 million in Q2 2026.”
“Dietary supplements revenue grew 19.1% to $11.0 million in Q1 2026.”
Focus on restoring procedure revenue growth and achieving full-year 2026 revenue above $175 million, revising prior guidance due to voluntary product recall impacts.
Over the trailing year it converted 1.14x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
8 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.